Expert Review of Neurotherapeutics最新文献

New trends in the treatment of blepharospasm: replacing the standardized approach with a personalized approach. 眼睑痉挛治疗的新趋势：以个性化方法取代标准化方法。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-07-14 DOI: 10.1080/14737175.2025.2532080

Laura M Scorr, Hyder A Jinnah

{"title":"New trends in the treatment of blepharospasm: replacing the standardized approach with a personalized approach.","authors":"Laura M Scorr, Hyder A Jinnah","doi":"10.1080/14737175.2025.2532080","DOIUrl":"10.1080/14737175.2025.2532080","url":null,"abstract":"Introduction: Blepharospasm is a type of dystonia associated with overactivity of the orbicularis oculi and nearby muscles causing significant disability. Available treatments are only symptomatic, and many patients experience disability related to incomplete symptom relief.Areas covered: The authors provide a review the phenomenology of blepharospasm and its usual treatments. The evidence for botulinum toxin, oral pharmaceuticals and surgical treatments are summarized. Despite considerable phenotypic heterogeneity, the literature indicates a standardized approach to treatment is often pursued. PubMed was used as the primary source database for the literature reviewed relating to the treatment of blepharospasm published between April 1985 and May 2025.Expert opinion: Although a standardized approach to treatment is common, a customized approach with attention to the particular combination of motor and non-motor symptoms occurring in individual patients improves therapeutic outcomes. The anatomical rationale and experience supporting a more personalized treatment strategy is emphasized. Also summarized are specific topics and strategies that are the subject of ongoing research to optimize the care of blepharospasm in the future.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-9"},"PeriodicalIF":3.4,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacotherapeutic approaches for the effective treatment of postoperative delirium: the state of play. 药物治疗方法对术后谵妄的有效治疗：发挥状态。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-07-10 DOI: 10.1080/14737175.2025.2532075

Eric Toyota, Verinder Sharma

{"title":"Pharmacotherapeutic approaches for the effective treatment of postoperative delirium: the state of play.","authors":"Eric Toyota, Verinder Sharma","doi":"10.1080/14737175.2025.2532075","DOIUrl":"https://doi.org/10.1080/14737175.2025.2532075","url":null,"abstract":"Introduction: Post-operative delirium (POD) is a common neuropsychiatric complication that is associated with increased morbidity, prolonged hospital stays, and persistent cognitive deficits. Despite its clinical relevance, pharmacologic treatment options remain limited and inconsistently supported by evidence.Areas covered: In this review, the authors synthesize the current understanding of pathophysiological mechanisms underlying POD then critically evaluate the evidence around pharmacotherapeutic interventions, focusing on the use of antipsychotics, cholinesterase inhibitors, sleep-wake cycle modulators, and dexmedetomidine, in the treatment of established delirium. Relevant articles were identified using PubMed, EMBASE, and Cochrane databases.Expert opinion: There remains insufficient evidence to support the routine use of pharmacologic interventions in the treatment of POD. While the evidence supporting dexmedetomidine seems most promising, its clinical significance is questionable and therefore its impact is likely in prevention rather than treatment. Various methodological challenges, including heterogeneity in trial design and insufficient stratification by delirium subtype, hinder generalizability of study results and advancements in how delirium is understood. Future progress will depend on reconceptualizing delirium away from a purely descriptive condition and toward a heterogenous, biologically driven disorder.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-14"},"PeriodicalIF":3.4,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the natural age cutoff point for primary-progressive multiple sclerosis therapy. 探索原发性进展性多发性硬化治疗的自然年龄截止点。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-07-10 DOI: 10.1080/14737175.2025.2531046

Robert Zivadinov, Bianca Weinstock-Guttman

引用次数: 0

Contemporary perspectives in cerebral amyloid angiopathy. 脑淀粉样血管病的当代观点。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-07-06 DOI: 10.1080/14737175.2025.2526113

Amina Sellimi, Julian Schwartze, Fiona Humphries, Larysa Panteleienko, Dermot Mallon, Gargi Banerjee, David J Werring

{"title":"Contemporary perspectives in cerebral amyloid angiopathy.","authors":"Amina Sellimi, Julian Schwartze, Fiona Humphries, Larysa Panteleienko, Dermot Mallon, Gargi Banerjee, David J Werring","doi":"10.1080/14737175.2025.2526113","DOIUrl":"10.1080/14737175.2025.2526113","url":null,"abstract":"Introduction: Cerebral amyloid angiopathy (CAA) is a leading cause of intracranial hemorrhage and cognitive decline, resulting from amyloid-β accumulation in the walls of small cortical and leptomeningeal arterioles. While models of pathogenesis exist, the mechanisms leading to the diverse clinical manifestations of CAA remain largely unknown. There are no proven treatments, but a few clinical trials are ongoing. Meanwhile, emerging anti-amyloid-β therapies and managing patients with comorbidities including atrial fibrillation complicate clinical-practice in peopel with CAA.Areas covered: Herein, the authors provide their perspectives on CAA from initial amyloid-β deposition to clinical disease manifestations. They also discuss the emergence of iatrogenic CAA and the potential role of inflammation across CAA, questioning the concept of a single entity. Finally, the authors examine management challenges, future research horizons, and treatment directions.Expert opinion: Recent insights challenge the traditional view of a linearly progressive disease, suggesting a dynamic natural history with periods of high activity and remission. Inflammation is a topic of active investigation, with potential therapeutic relevance. Challenges remain, including the need for improved neuroimaging and fluid biomarkers for noninvasive early diagnosis. Iatrogenic CAA is a recently described amyloid-β prion disease in younger people, with known Aβ innoculation and exposure times, providing a potential 'pure' model of CAA. Research into limiting Aβ production, improving perivascular clearance, or modifying vascular remodeling and inflammation may guide novel therapeutics.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-24"},"PeriodicalIF":3.4,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of the rivastigmine 13.3 mg/24h transdermal patch as a treatment option for Alzheimer's disease. 利瓦斯汀13.3 mg/24h透皮贴剂作为阿尔茨海默病治疗选择的概述

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-07-03 DOI: 10.1080/14737175.2025.2527211

Juan Fortea, Elena Ferrer-Picón

{"title":"An overview of the rivastigmine 13.3 mg/24h transdermal patch as a treatment option for Alzheimer's disease.","authors":"Juan Fortea, Elena Ferrer-Picón","doi":"10.1080/14737175.2025.2527211","DOIUrl":"10.1080/14737175.2025.2527211","url":null,"abstract":"Introduction: Rivastigmine, a cholinesterase inhibitor, was first approved for the treatment of Alzheimer's disease (AD) dementia more than 20 years ago. Initially available as an oral formulation, a transdermal system was subsequently developed with the aim of improving tolerability while providing similar efficacy. Transdermal rivastigmine is approved for the treatment of severe AD as well as mild-to-moderate AD.Areas covered: Herein, the authors review randomized clinical trials, meta-analyses, and post-marketing observational studies involving the rivastigmine 13.3 mg/24 h patch for the treatment of patients with AD.Expert opinion: Cholinesterase inhibitors are a mainstay of the symptomatic treatment of patients with AD. Rivastigmine is available as oral and transdermal formulations, with the latter providing improved tolerability and convenience while maintaining efficacy. The high-dose 13.3 mg/24 h patch might offer benefits for some patients compared to the lower dose patch (4.6 mg/24 h) in patients with mild-to-moderate or severe AD, showing improvements in daily functioning and global clinical status on top of the cognitive benefits. The ability to titrate up to a dose of 13.3 mg/24 h provides an option for patients with severe AD or with an inadequate response to lower doses of rivastigmine.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-11"},"PeriodicalIF":3.4,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing treatment for pediatric multiple sclerosis. 小儿多发性硬化症的优化治疗。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-07-01 Epub Date: 2025-05-30 DOI: 10.1080/14737175.2025.2508777

Nail Benallegue, Fabien Rollot, David-Axel Laplaud

{"title":"Optimizing treatment for pediatric multiple sclerosis.","authors":"Nail Benallegue, Fabien Rollot, David-Axel Laplaud","doi":"10.1080/14737175.2025.2508777","DOIUrl":"10.1080/14737175.2025.2508777","url":null,"abstract":"Introduction: Pediatric-onset multiple sclerosis (POMS) differs from adult MS in its clinical characteristics and disease course. POMS exhibits a heightened inflammatory activity with higher relapse rates and lesion load, alongside less early physical disability but more pronounced cognitive impairment and impaired brain growth.Areas covered: This review examines treatment strategy in POMS based on safety and efficacy data from observational studies and randomized controlled trials. This article is based on a literature search conducted using MEDLINE and Google Scholar for the period of 2000 to 2024.Expert opinion: High-efficacy therapies, including fingolimod, natalizumab, and anti-CD20 therapies, have demonstrated superior disease control and disability prevention. Early initiation of HET is increasingly recommended to optimize outcomes and preserve quality of life.Low/moderate-efficacy therapies, such as interferons, glatiramer acetate, teriflunomide, dimethyl fumarate should be reserved for patients with mild disease. While long-term safety data, personalized prognostic markers and de-escalation strategies are still needed, high-efficacy therapies provide a promising standard of care, especially given enhanced neuroinflammatory activity in POMS. Future research should prioritize strategies to balance disease control with adverse effects (AEs), accounting for aging and individual disease trajectories, to improve long-term quality of life in POMS patients.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"819-855"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144181952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Behavioural difficulties in fragile X syndrome: current pharmacological options and potential future developments. 脆性X综合征的行为困难：当前的药理学选择和潜在的未来发展。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-07-01 Epub Date: 2025-06-05 DOI: 10.1080/14737175.2025.2510408

Andrew C Stanfield, Andrew G McKechanie

{"title":"Behavioural difficulties in fragile X syndrome: current pharmacological options and potential future developments.","authors":"Andrew C Stanfield, Andrew G McKechanie","doi":"10.1080/14737175.2025.2510408","DOIUrl":"10.1080/14737175.2025.2510408","url":null,"abstract":"Introduction: Fragile X Syndrome (FXS) is the most frequent inherited form of intellectual disability and a common cause of autism spectrum disorders and other neurodevelopmental conditions. It is commonly associated with hyperarousal, anxiety, and behavioral difficulties such as agitation, self-injurious behavior, and aggression.Areas covered: This narrative review covers the physical, cognitive, and behavioral phenotype associated with FXS and the evidence for pharmacological interventions for behavioral difficulties, including those prescribed on the basis of symptoms and those aimed at the pathophysiological mechanisms of FXS ('targeted' interventions). Consideration is then given to the evidence for novel targeted treatments currently in later stages of clinical development.Expert opinion: The first-line management of behavioral difficulties are non-pharmacological interventions, and there are only a few studies in FXS to guide pharmacological approaches. Identification and management of anxiety and ADHD, which contribute to behavioral difficulties, are important steps before considering antipsychotic treatment for agitation, aggression, or self-injurious behavior. The evidence for repurposed targeted treatments remains based on small RCTs or open-label studies; therapeutic trials of these interventions therefore need close monitoring. Multiple novel medications are in clinical development; genetic therapies remain preclinical but are likely to be important in the coming years.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"857-867"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Insights and Strategies to Managing Depression Subtypes Associated with Tobacco dependence: A Response to the Letter to the Editor. 管理与烟草依赖相关的抑郁症亚型的临床见解和策略：对致编辑的信的回应。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-07-01 Epub Date: 2025-05-14 DOI: 10.1080/14737175.2025.2506463

Stefania Chiappini, Gaia Sampogna, Antonio Ventriglio, Giulia Menculini, Valerio Ricci, Mauro Pettorruso, Umberto Volpe, Giovanni Martinotti

引用次数: 0

Multimodal approaches to the treatment of personality disorder. 治疗人格障碍的多模式方法。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-07-01 Epub Date: 2025-06-19 DOI: 10.1080/14737175.2025.2515066

Peter Tyrer, Jacob King, Roger Mulder

{"title":"Multimodal approaches to the treatment of personality disorder.","authors":"Peter Tyrer, Jacob King, Roger Mulder","doi":"10.1080/14737175.2025.2515066","DOIUrl":"10.1080/14737175.2025.2515066","url":null,"abstract":"Introduction: Personality disorder is the most common of all psychiatric disorders and is best perceived as a diagnostic spectrum extending from no personality dysfunction to severe personality disorder. The position on the spectrum is determined mainly by problems in interpersonal social dysfunction, self-perception and awareness, and dangers to the self and others.Areas covered: We examine psychological and psychodynamic treatments, pharmacotherapy, neuromodulation and other related approaches, environmental treatments, and therapeutic communities. Although many published studies refer to individual categories, these are now linked to the diagnostic spectrum in this review.Expert opinion: There is some evidence that focused psychological treatments linked to problem solving (STEPPS), mentalization based therapy and dialectical behavior therapy, are successful in treating moderately severe personality disorder, especially regarding self-harm, but there is also benefit from well organized standard care that is similarly effective. There is no good evidence that drug treatment is of real value in personality disorder. Brain stimulation approaches have limited evidence. Psychodynamic approaches, environmental interventions, nidotherapy, and therapeutic communities appear to be of some value, but good data are few. Long-term studies of treatment effectiveness are few but some show that personality disorder can respond to treatment and remit.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"869-879"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing cognitive impairment among pediatric epilepsies: a systematic review. 评估儿童癫痫患者的认知障碍：一项系统综述。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-07-01 Epub Date: 2025-06-05 DOI: 10.1080/14737175.2025.2508776

Erika Maria Giannola, Laura Siri, Pasquale Striano, Antonella Riva

{"title":"Assessing cognitive impairment among pediatric epilepsies: a systematic review.","authors":"Erika Maria Giannola, Laura Siri, Pasquale Striano, Antonella Riva","doi":"10.1080/14737175.2025.2508776","DOIUrl":"10.1080/14737175.2025.2508776","url":null,"abstract":"Background: Epilepsy is a chronic neurological disorder that varies both for etiopathology and impact on cognitive, intellectual, and adaptive development in children with epilepsy (CWE). CWE may present with reduced attention, memory as well as learning skills, and impaired executive and emotional-behavioral functioning, which can impact both the patient's and their family's Quality of Life (QoL).Methods: This systematic review investigates the tools and scales used to assess cognition in CWE, following the PRISMA guidelines. PubMed was used as primary source database and studies published between January 2020 and December 2024 were reviewed for inclusion/exclusion criteria.Results: The authors' search yielded 3,398 articles of which 2,486 (73%) papers were excluded based on title and abstract only. Of the 912 remaining records, 844 did not meet the inclusion criteria. Sixty-eight studies met the inclusion criteria. The total number of epilepsy patients (EP) in the included studies was 4,530. The Wechsler intelligence scale for children was the most administered test to evaluate cognitive impairment.Conclusions: The included studies highlighted the relevance of the impaired neuropsychological functioning in CWE, although deep heterogeneity in the assessment still invalidates comparability. Further research is needed to provide comprehensive care of CWE, enhancing cognitive functions and considering the impact of the illness on QoL and mental health.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"753-772"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0